OTCMKTS:PBSV Pharma-Bio Serv (PBSV) Stock Price, News & Analysis $0.60 +0.09 (+17.65%) As of 06/25/2025 02:15 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Pharma-Bio Serv Stock (OTCMKTS:PBSV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharma-Bio Serv alerts:Sign Up Key Stats Today's Range$0.60▼$0.6050-Day Range$0.43▼$0.6052-Week Range$0.31▼$0.67Volume7,000 shsAverage Volume7,132 shsMarket Capitalization$13.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.Read More… Pharma-Bio Serv Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScorePBSV MarketRank™: Pharma-Bio Serv scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pharma-Bio Serv. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharma-Bio Serv is -60.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharma-Bio Serv is -60.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharma-Bio Serv has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pharma-Bio Serv's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Pharma-Bio Serv has been sold short.Short Interest Ratio / Days to CoverPharma-Bio Serv has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharma-Bio Serv has recently increased by 50.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharma-Bio Serv does not currently pay a dividend.Dividend GrowthPharma-Bio Serv does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the float of Pharma-Bio Serv has been sold short.Short Interest Ratio / Days to CoverPharma-Bio Serv has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharma-Bio Serv has recently increased by 50.00%, indicating that investor sentiment is decreasing significantly. News and Social Media0.9 / 5News Sentiment-0.36 News SentimentPharma-Bio Serv has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pharma-Bio Serv this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharma-Bio Serv insiders have not sold or bought any company stock.Percentage Held by Insiders12.60% of the stock of Pharma-Bio Serv is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Pharma-Bio Serv's insider trading history. Receive PBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter. Email Address PBSV Stock News HeadlinesPBSV Pharma-Bio Serv, Inc. - Seeking AlphaJune 26 at 12:43 AM | seekingalpha.comOTC:PBSV Financials | Pharma-Bio Serv Inc - Investing.comJune 26 at 12:43 AM | investing.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.June 27 at 2:00 AM | Priority Gold (Ad)Pharma-Bio Serv (OTCMKTS:PBSV) and Gartner (NYSE:IT) Critical ReviewJune 26 at 2:41 AM | americanbankingnews.comPBSV Decisions Paying OffJune 19, 2025 | msn.comPharma-Bio Serv Inc. (OTCMKTS:PBSV) Sees Large Growth in Short InterestJune 18, 2025 | americanbankingnews.comPBSV Returns to GrowthMarch 18, 2025 | msn.comPharma-Bio Serv Inc.: Pharma-Bio Serv Announces Full Year ResultsJanuary 31, 2025 | finanznachrichten.deSee More Headlines PBSV Stock Analysis - Frequently Asked Questions How have PBSV shares performed this year? Pharma-Bio Serv's stock was trading at $0.5499 at the start of the year. Since then, PBSV shares have increased by 9.1% and is now trading at $0.60. View the best growth stocks for 2025 here. How were Pharma-Bio Serv's earnings last quarter? Pharma-Bio Serv Inc. (OTCMKTS:PBSV) announced its quarterly earnings results on Monday, March, 17th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.02 by $0.35. The company earned $2.47 million during the quarter, compared to analysts' expectations of $2.70 million. Pharma-Bio Serv had a negative net margin of 1.96% and a negative trailing twelve-month return on equity of 1.47%. How do I buy shares of Pharma-Bio Serv? Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharma-Bio Serv own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharma-Bio Serv investors own include AT&T (T), Annaly Capital Management (NLY), BlackRock Multi-Sector Income Trust (BIT), GE Aerospace (GE), Exxon Mobil (XOM), Enterprise Products Partners (EPD) and First BanCorp. (FBP). Company Calendar Last Earnings3/17/2025Today6/27/2025Next Earnings (Estimated)9/15/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Consulting Sub-IndustryBusiness Services Current SymbolOTCMKTS:PBSV CIK1304161 Webwww.pharmabioserv.com Phone(787) 278-2709Fax787-796-5168Employees185Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio5.45 P/E GrowthN/ANet Income-$780 thousand Net Margins-1.96% Pretax Margin-2.01% Return on Equity-1.47% Return on Assets-1.21% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.54 Sales & Book Value Annual Sales$9.51 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book1.13Miscellaneous Outstanding Shares22,930,000Free Float20,043,000Market Cap$13.76 million OptionableNot Optionable Beta0.68 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:PBSV) was last updated on 6/27/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma-Bio Serv Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharma-Bio Serv With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.